Trials / Completed
CompletedNCT05124925
Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.
An Open-label, Non-randomized, Biopsy-based Mechanistic Study on Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ianalumab in Patients With Sjögren's Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments
Detailed description
This is an open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ianalumab | Ianalumab VAY736 150mg/1ml Solution for injection |
Timeline
- Start date
- 2022-07-27
- Primary completion
- 2024-06-26
- Completion
- 2026-01-05
- First posted
- 2021-11-18
- Last updated
- 2026-02-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05124925. Inclusion in this directory is not an endorsement.